{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,26]],"date-time":"2026-09-26T01:51:14Z","timestamp":1790387474475,"version":"4.1.0"},"reference-count":35,"publisher":"Wiley","issue":"2","license":[{"start":{"date-parts":[[2006,12,7]],"date-time":"2006-12-07T00:00:00Z","timestamp":1165449600000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/onlinelibrary.wiley.com\/termsAndConditions#vor"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Cancer"],"published-print":{"date-parts":[[2007,1,15]]},"abstract":"<jats:title>Abstract<\/jats:title><jats:sec><jats:title>BACKGROUND.<\/jats:title><jats:p>Oral mucositis (OM) is a frequent complication of mucotoxic cancer therapy, causing significant oral pain, increased infection risk, and impaired functioning. The efficacy and safety of Saforis (glutamine) powder in UpTec for oral suspension was evaluated for the prevention and treatment of OM.<\/jats:p><\/jats:sec><jats:sec><jats:title>METHODS.<\/jats:title><jats:p>Three hundred twenty\u2010six patients developing World Health Organization (WHO) grade \u22652 OM during a chemotherapy screening cycle were randomized to Saforis (n = 163) or placebo (n = 163) 3 times\/day during their next chemotherapy cycle (Treatment Cycle 1). Patients were crossed over to the alternate treatment during Treatment Cycle 2. As prespecified in the statistical plan, because of a carryover effect in Treatment Cycle 2 the primary efficacy analysis was based on Treatment Cycle 1 only.<\/jats:p><\/jats:sec><jats:sec><jats:title>RESULTS.<\/jats:title><jats:p>Compared with placebo, Saforis significantly reduced the incidence of clinically significant WHO grade \u22652 OM (38.7% vs. 49.7%; <jats:italic>P<\/jats:italic> = .026) and severe WHO grade \u22653 OM (1.2% vs. 6.7%; <jats:italic>P<\/jats:italic> = .005) in Treatment Cycle 1. Saforis also significantly reduced the worst Oral Mucositis Assessment Scale ulceration score in Treatment Cycle 1 compared with placebo (mean, 0.23 \u00b1 0.39 vs. 0.32 \u00b1 0.45; <jats:italic>P<\/jats:italic> = .013). Patients receiving Saforis in Treatment Cycle 1 had a lower\u2010than\u2010expected OM incidence when crossed over to placebo in Treatment Cycle 2, indicating a significant carryover effect (<jats:italic>P<\/jats:italic> = .027). The incidence of treatment\u2010emergent adverse events was similar between groups.<\/jats:p><\/jats:sec><jats:sec><jats:title>CONCLUSIONS.<\/jats:title><jats:p>Saforis is safe and effective for preventing and treating OM in patients receiving mucotoxic cancer chemotherapy. Cancer 2007. \u00a9 2006 American Cancer Society.<\/jats:p><\/jats:sec>","DOI":"10.1002\/cncr.22384","type":"journal-article","created":{"date-parts":[[2006,12,7]],"date-time":"2006-12-07T15:47:04Z","timestamp":1165506424000},"page":"322-331","source":"Crossref","is-referenced-by-count":103,"title":["Randomized, placebo\u2010controlled trial of Saforis for prevention and treatment of oral mucositis in breast cancer patients receiving anthracycline\u2010based chemotherapy"],"prefix":"10.1002","volume":"109","author":[{"given":"Douglas E.","family":"Peterson","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"James B.","family":"Jones","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"suffix":"II","given":"Robert G.","family":"Petit","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"311","published-online":{"date-parts":[[2007,1,8]]},"reference":[{"key":"e_1_2_5_2_2","doi-asserted-by":"publisher","DOI":"10.1002\/cncr.20163"},{"key":"e_1_2_5_3_2","doi-asserted-by":"publisher","DOI":"10.1002\/cncr.20162"},{"key":"e_1_2_5_4_2","doi-asserted-by":"publisher","DOI":"10.1002\/cncr.11671"},{"key":"e_1_2_5_5_2","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2001.19.8.2201"},{"key":"e_1_2_5_6_2","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2005.01.8010"},{"key":"e_1_2_5_7_2","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2005.08.008"},{"key":"e_1_2_5_8_2","doi-asserted-by":"publisher","DOI":"10.1002\/cncr.11382"},{"key":"e_1_2_5_9_2","volume-title":"Kepivance (palifermin) [package insert]","year":"2004"},{"key":"e_1_2_5_10_2","doi-asserted-by":"publisher","DOI":"10.1007\/s003840050199"},{"key":"e_1_2_5_11_2","doi-asserted-by":"publisher","DOI":"10.1016\/S1357-2725(01)00143-1"},{"key":"e_1_2_5_12_2","doi-asserted-by":"publisher","DOI":"10.1016\/S0261-5614(03)00040-2"},{"key":"e_1_2_5_13_2","doi-asserted-by":"publisher","DOI":"10.1006\/cyto.2002.1027"},{"key":"e_1_2_5_14_2","doi-asserted-by":"publisher","DOI":"10.1093\/jn\/133.10.3065"},{"key":"e_1_2_5_15_2","doi-asserted-by":"publisher","DOI":"10.1016\/0167-4889(87)90153-4"},{"key":"e_1_2_5_16_2","doi-asserted-by":"publisher","DOI":"10.1016\/S0305-7372(03)00133-6"},{"key":"e_1_2_5_17_2","first-page":"640","article-title":"Pharmacokinetics (PK) of Saforis administered to healthy subjects and stem cell transplant (SCT) patients with WHO grade > 2 oral mucositis (OM) [Abstract 16\u2013115]","volume":"14","author":"Peterson D","year":"2006","journal-title":"Support Care Cancer."},{"key":"e_1_2_5_18_2","doi-asserted-by":"publisher","DOI":"10.1038\/sj.bmt.1705084"},{"key":"e_1_2_5_19_2","doi-asserted-by":"publisher","DOI":"10.1345\/aph.19168"},{"key":"e_1_2_5_20_2","doi-asserted-by":"publisher","DOI":"10.1016\/S0360-3016(99)00402-2"},{"key":"e_1_2_5_21_2","doi-asserted-by":"publisher","DOI":"10.1038\/bjc.1994.385"},{"key":"e_1_2_5_22_2","doi-asserted-by":"publisher","DOI":"10.1177\/0148607199023003117"},{"key":"e_1_2_5_23_2","first-page":"64","article-title":"Glutamine as a potential treatment for the prevention of chemotherapy\u2010induced mucositis","volume":"4","author":"Skubitz KM","year":"1994","journal-title":"J Infus Chemother."},{"key":"e_1_2_5_24_2","doi-asserted-by":"publisher","DOI":"10.1038\/nrc1318"},{"key":"e_1_2_5_25_2","doi-asserted-by":"publisher","DOI":"10.2165\/00003495-200565150-00010"},{"key":"e_1_2_5_26_2","doi-asserted-by":"publisher","DOI":"10.1177\/014860719001400417"},{"key":"e_1_2_5_27_2","first-page":"612a","article-title":"AES\u201014 facilitates rapid intracellular transport of high levels of L\u2010glutamine in mucosal epithelial cells [Abstract 2410]","volume":"19","author":"Petit R","year":"2000","journal-title":"Proc Am Soc Clin Oncol."},{"key":"e_1_2_5_28_2","first-page":"261b","article-title":"Aesgen\u201014 (uptake\u2010enhanced L\u2010glutamine suspension) reduces severe mucositis in acute radiation model where aqueous L\u2010glutamine suspension is ineffective [Abstract 2861]","volume":"21","author":"Petit RG","year":"2002","journal-title":"Proc Am Soc Clin Oncol."},{"key":"e_1_2_5_29_2","doi-asserted-by":"publisher","DOI":"10.1038\/sj.bmt.1701317"},{"key":"e_1_2_5_30_2","doi-asserted-by":"publisher","DOI":"10.1002\/(SICI)1097-0142(19981001)83:7<1433::AID-CNCR22>3.0.CO;2-4"},{"key":"e_1_2_5_31_2","first-page":"725","article-title":"Phase III study: AES\u201014 in chemotherapy patients at risk for mucositis [Abstract 2917]","volume":"22","author":"Peterson DE","year":"2003","journal-title":"Proc Am Soc Clin Oncol."},{"key":"e_1_2_5_32_2","doi-asserted-by":"publisher","DOI":"10.1016\/S0022-2143(96)90082-7"},{"key":"e_1_2_5_33_2","doi-asserted-by":"publisher","DOI":"10.1002\/(SICI)1097-0142(19990515)85:10<2103::AID-CNCR2>3.0.CO;2-0"},{"key":"e_1_2_5_34_2","volume-title":"WHO handbook for reporting results in cancer treatment","author":"World Health Organization","year":"2006"},{"key":"e_1_2_5_35_2","first-page":"275","volume-title":"The design and analysis of clinical experience","author":"Fleiss JL","year":"1986"},{"key":"e_1_2_5_36_2","doi-asserted-by":"publisher","DOI":"10.1007\/s00520-003-0550-9"}],"container-title":["Cancer"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.wiley.com\/onlinelibrary\/tdm\/v1\/articles\/10.1002%2Fcncr.22384","content-type":"unspecified","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/acsjournals.onlinelibrary.wiley.com\/doi\/pdf\/10.1002\/cncr.22384","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,10,12]],"date-time":"2025-10-12T21:03:38Z","timestamp":1760303018000},"score":1,"resource":{"primary":{"URL":"https:\/\/acsjournals.onlinelibrary.wiley.com\/doi\/10.1002\/cncr.22384"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2007,1,8]]},"references-count":35,"journal-issue":{"issue":"2","published-print":{"date-parts":[[2007,1,15]]}},"alternative-id":["10.1002\/cncr.22384"],"URL":"https:\/\/doi.org\/10.1002\/cncr.22384","archive":["Portico"],"relation":{},"ISSN":["0008-543X","1097-0142"],"issn-type":[{"value":"0008-543X","type":"print"},{"value":"1097-0142","type":"electronic"}],"subject":[],"published":{"date-parts":[[2007,1,8]]}}}